Peyer

Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award

Retrieved on: 
Tuesday, December 5, 2023
Research, Therapy, IND, Risk, Peyer, Telomere, Patient, Metabolism, Science, Health, Telos, Ageing, Infection, Cancer, Cell, Cellular senescence, Weight loss, Pharmaceutical industry, Amplifier, Cambrian

NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Cambrian Bio, a New York-based clinical-stage drug development company, is among the honorees for Fast Company's Next Big Things in Tech 2023.

Key Points: 
  • NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Cambrian Bio, a New York-based clinical-stage drug development company, is among the honorees for Fast Company's Next Big Things in Tech 2023.
  • The purpose of the award is to celebrate technological breakthroughs that are changing the way we live.
  • Each program is launched within Cambrian in collaboration with top drug developers and leading scientists.
  • "Thank you, Fast Company, for honoring our team's work as we create new technology to improve the health and performance of our cells and bodies," said James Peyer, CEO of Cambrian Bio.

Cambrian Biopharma CEO James Peyer Named 2022 "BioTech Company CEO of the Year" By BioTech Breakthrough

Retrieved on: 
Friday, November 4, 2022
People, Leadership, Company, Science, Therapy, Founder, Sutro Biopharma, Multimedia, Yissum Research Development Company of the Hebrew University, Biotechnology, Peyer, Solution, Woman, Ageing, Safety, Tornado, Quality of life, CEO, Longevity, Geroprotector, Health, Drug development, Disco, Year, Photoionization, Efficiency, Fine chemical, Pharmaceutical industry, Cambrian, Genomics

NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today announced that its CEO, James Peyer, has been selected as "BioTech Company CEO of the Year" in the second annual BioTech Breakthrough Awards, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Key Points: 
  • James Peyer, Ph.D., is CEO and Founder of Cambrian Biopharma, which is bridging the gap between academic discovery and drug development, under their Distributed Development Company (or DisCo) model.
  • Since 2019, Peyer's Cambrian has grown from three drugs more than a dozen therapeutics that are currently in development.
  • "Thank you so much to BioTech Breakthrough for honoring me and the work of my entire team in this way.
  • Congratulations to James Peyer on winning 'BioTech Company CEO of the Year' for 2022."

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

Retrieved on: 
Monday, March 14, 2022
IgA nephropathy, Nasdaq, Peyer, Primary, Kidney disease, Kidney, Social conditions in Honduras, USD, Company, Partnership, Ministry, Immunoglobulin A, Degenerative disease, Mortality, Autoantibody, CALT, NDA, Nasdaq Stockholm, News, Ileum, Infection, Budesonide, Doctor of Philosophy, Patient, Gut, Kidney bean, Peyer's patch, Terminology, HKEX, A, Therapy, Nationwide, CMC, Pharmaceutical industry, MD, Welander, Food

SHANGHAI, March 13, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that it has entered into a license agreement with Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) to develop and commercialize NEFECON for the treatment of primary IgA nephropathy (IgAN) in South Korea, expanding its license in addition to rights held in Greater China and Singapore. The deal signals the Company's latest efforts to further enhance its international commercial footprint.

Key Points: 
  • "South Korea's sophisticated healthcare model enables innovative medicines such as NEFECON to have a higher potential likelihood of healthcare coverage once approved.
  • Under the terms of the agreement, Calliditas receives an initial upfront payment of USD$3 million at signing of the agreement.
  • In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON in Mainland China, Hong Kong, Macau, Taiwan and Singapore.
  • The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories.

IgA Nephropathy (IgAN): Global Market Insights, Epidemiology, and Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 24, 2021
Health, Pharmaceutical, Patient, Antibody, News, Blood pressure, Review, Kidney disease, Protocol 1, PESTLE, Technology, Disease, TARGIT, Chronic kidney disease, Physiology, Acquisition, Immunoglobulin A, BP, Growth–share matrix, Awareness, SWOT, Prevalence, USD, Injection, Novartis, Therapy, Budesonide, Immunoglobulin G, Health insurance coverage in the United States, SME, AT1, Research, Stomach, Risk, ETA, Plasma protein binding, Lists of people executed in the United States, III, Porter's five forces analysis, II, Toxicity, Peyer, Proteinuria, Online gambling, Pharmaceutical industry, Medical imaging, Medical device, Health insurance, Marketing, Grocery store, Renewable energy

The "IgA Nephropathy (IgAN) - Market Insights, Epidemiology, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "IgA Nephropathy (IgAN) - Market Insights, Epidemiology, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The disease epidemiology covered in the report provides historical and forecasted IgA nephropathy epidemiology segmented as the prevalence of IgA nephropathy, gender-specific cases of IgA nephropathy, and age-specific cases of IgA nephropathy.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global IgA nephropathy market.
  • To understand the future market competition in the IgA nephropathy market and an Insightful review of the key market drivers and barriers.